Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRS Antares Pharma	$5.59	$5.59	$3.11 ▼ $5.60	$955.06M	1.15	3.29 million shs	6 shs
OSUR OraSure Technologies	$3.10 +1.6%	$2.84	$2.36 ▼ $4.92	$231.88M	0.45	745,489 shs	682,037 shs
PLSE Pulse Biosciences	$16.03 -6.4%	$16.32	$13.50 ▼ $25.00	$1.08B	1.56	176,138 shs	116,090 shs
SRDX Surmodics	$30.87 -0.5%	$29.03	$26.00 ▼ $42.25	$441.41M	1.31	221,371 shs	75,417 shs
XENT Intersect ENT	$28.24	$28.24	$15.92 ▼ $28.25	$954.91M	1.45	351,526 shs	14,512 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRS Antares Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
OSUR OraSure Technologies	+1.64%	+0.65%	+6.16%	+5.80%	-25.84%
PLSE Pulse Biosciences	-6.37%	+8.34%	-4.18%	-0.06%	+7.87%
SRDX Surmodics	-0.48%	+2.95%	+6.48%	+8.35%	-26.67%
XENT Intersect ENT	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRS Antares Pharma	1.8851 of 5 stars	0.0	0.0	0.0	3.6	0.6	0.8	3.1
OSUR OraSure Technologies	2.5558 of 5 stars	1.0	3.0	0.0	4.2	2.1	1.7	0.6
PLSE Pulse Biosciences	3.8699 of 5 stars	3.5	0.0	0.0	4.2	1.9	4.2	0.0
SRDX Surmodics	4.3053 of 5 stars	3.3	4.0	0.0	3.4	1.0	1.7	1.9
XENT Intersect ENT	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRS Antares Pharma	0.00	N/A	N/A	N/A
OSUR OraSure Technologies	2.00	Hold	$3.00	-3.23% Downside
PLSE Pulse Biosciences	3.00	Buy	$22.00	37.24% Upside
SRDX Surmodics	2.50	Moderate Buy	$43.00	39.29% Upside
XENT Intersect ENT	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATRS, PLSE, OSUR, SRDX, and XENT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
5/19/2025	OSUR OraSure Technologies	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	In-Line ➝ In-Line	$3.00 ➝ $3.00
4/30/2025	SRDX Surmodics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRS Antares Pharma	$183.98M	5.19	$0.13 per share	43.89	$1.03 per share	5.43
OSUR OraSure Technologies	$185.83M	1.25	$0.04 per share	79.85	$5.50 per share	0.56
PLSE Pulse Biosciences	$700K	1,540.48	N/A	N/A	$1.87 per share	8.57
SRDX Surmodics	$126.08M	3.50	$0.31 per share	99.78	$8.33 per share	3.71
XENT Intersect ENT	$106.75M	8.95	N/A	N/A	($2.06) per share	-13.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRS Antares Pharma	$46.29M	$0.24	23.29	25.41	N/A	21.90%	7.43%	4.92%	N/A
OSUR OraSure Technologies	-$19.50M	-$0.42	N/A	N/A	N/A	-19.77%	-5.86%	-5.20%	8/5/2025 (Estimated)
PLSE Pulse Biosciences	-$53.58M	N/A	0.00	∞	N/A	N/A	-68.44%	-58.17%	8/14/2025 (Estimated)
SRDX Surmodics	-$11.54M	-$1.39	N/A	38.59	N/A	-16.34%	-7.10%	-4.77%	7/30/2025 (Estimated)
XENT Intersect ENT	-$159.63M	-$4.79	N/A	N/A	N/A	-161.94%	-709.52%	-48.18%	N/A

Latest ATRS, PLSE, OSUR, SRDX, and XENT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	OSUR OraSure Technologies	-$0.15	N/A	N/A	N/A	$30.52 million	N/A
7/30/2025	Q3 2025	SRDX Surmodics	-$0.21	N/A	N/A	N/A	$28.04 million	N/A
5/8/2025	Q1 2025	PLSE Pulse Biosciences	N/A	-$0.25	N/A	-$0.25	N/A	N/A
4/30/2025	Q2 2025	SRDX Surmodics	-$0.06	-$0.13	-$0.07	-$0.36	$32.23 million	$28.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRS Antares Pharma	N/A	N/A	N/A	N/A	N/A
OSUR OraSure Technologies	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A
SRDX Surmodics	N/A	N/A	N/A	N/A	N/A
XENT Intersect ENT	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRS Antares Pharma	0.10	3.08	2.87
OSUR OraSure Technologies	N/A	12.34	10.94
PLSE Pulse Biosciences	N/A	15.58	15.58
SRDX Surmodics	0.27	5.14	3.99
XENT Intersect ENT	6.89	1.88	1.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRS Antares Pharma	50.41%
OSUR OraSure Technologies	93.50%
PLSE Pulse Biosciences	76.95%
SRDX Surmodics	96.63%
XENT Intersect ENT	92.47%

Insider Ownership

Company	Insider Ownership
ATRS Antares Pharma	5.90%
OSUR OraSure Technologies	3.90%
PLSE Pulse Biosciences	71.50%
SRDX Surmodics	8.90%
XENT Intersect ENT	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRS Antares Pharma	201	170.85 million	160.77 million	Optionable
OSUR OraSure Technologies	840	74.80 million	71.88 million	Optionable
PLSE Pulse Biosciences	140	67.27 million	19.17 million	Optionable
SRDX Surmodics	450	14.30 million	13.03 million	Optionable
XENT Intersect ENT	433	33.81 million	33.10 million	Optionable

ATRS, PLSE, OSUR, SRDX, and XENT Headlines

Recent News About These Companies

Zee Ent. - Zee Entertainment Enterprises Share Price

August 2, 2024 | economictimes.indiatimes.com

Kiatnakin Bank PCL (KKP)

July 26, 2024 | investing.com

At the Intersection of Law & Policy

March 1, 2024 | slu.eduS

74-year-old woman killed in east Charlotte crash, CMPD says

December 6, 2023 | wsoctv.comW

What 4 Execs Want People To Know About the Intersection Between the Justice System and Behavioral Health

November 29, 2023 | medcitynews.comM

Traffic signal installed at notorious Riverside intersection where crash killed 8-year-old

November 4, 2023 | nbclosangeles.comN

Rogue Robotaxi Tries To Drive Down Footpath, Reverses Into Intersection

October 30, 2023 | jalopnik.comJ

XENT Historical Data

October 21, 2023 | investing.com

Video shows Brightline train goes through intersection while bars up; officials explain why

October 5, 2023 | tcpalm.comT

Intersection Into Proposed Cricket Stadium OK'd By Kendall Board

September 26, 2023 | patch.com

Music At The Intersection Festival Tells St. Louis’ Rich Musical History

September 12, 2023 | yahoo.com

4-way stop coming to Poinciana intersection where crash killed 4

September 12, 2023 | clickorlando.comC

Weaver intersection to finally open, Plainview close as extension work continues

September 9, 2023 | news-leader.comN

More social space, less traffic noise: The award-winning reno on a busy intersection

September 2, 2023 | smh.com.au

Code of conduct prepared for peace, intersect harmony during Muharram: Ayaz

August 31, 2023 | radio.gov.pkR

Euclid looking to increase safety at intersection following study

August 28, 2023 | news-herald.comN

Cruise car reportedly swerves in backhoe's way, is busted in SF intersection

August 28, 2023 | sfgate.com

Toronto is about to get a new type of intersection unlike any it's seen before

August 27, 2023 | blogto.comB

Watch: US Woman Points Gun At Cars On Intersection, Cop Drives Cruiser Into Her

August 19, 2023 | ndtv.comN

Lawsuit claims Iowa City teens were 'drag racing' when they struck Jennifer Russell's car in an intersection

July 19, 2023 | press-citizen.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Top Stocks Under $20 Riding the “Made in America” Wave
By Chris Markoch | July 3, 2025
View 3 Top Stocks Under $20 Riding the “Made in America” Wave
IGM ETF: Expand Tech Exposure With Top AI Leaders
By Jeffrey Neal Johnson | July 1, 2025
View IGM ETF: Expand Tech Exposure With Top AI Leaders
5 High-Yielding ETFs to Buy and Hold Forever
By Ryan Hasson | June 30, 2025
View 5 High-Yielding ETFs to Buy and Hold Forever

ATRS, PLSE, OSUR, SRDX, and XENT Company Descriptions

Antares Pharma NASDAQ:ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

OraSure Technologies NASDAQ:OSUR

$3.10 +0.05 (+1.64%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$3.04 -0.06 (-1.77%)

As of 07/11/2025 07:59 PM Eastern

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

Pulse Biosciences NASDAQ:PLSE

$16.03 -1.09 (-6.37%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$16.37 +0.34 (+2.13%)

As of 07/11/2025 07:21 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Surmodics NASDAQ:SRDX

$30.87 -0.15 (-0.48%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$30.86 -0.02 (-0.05%)

As of 07/11/2025 04:11 PM Eastern

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Intersect ENT NASDAQ:XENT

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time